press releases

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3 pivotal trial in newly diagnosed GBM which confirms the superior progression free and overall survival seen in… Read More

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma November 03, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that United Healthcare will cover Optune… Read More

Continued growth in active patients with 985 active patients at September 30, 2016, an increase of 110 percent from September 30, 2015, and 11 percent from June 30, 2016 Third quarter 2016 reported revenues of $21.7 million, reflecting 142 percent growth versus third quarter 2015 and 21… Read More

November 01, 2016 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will promote programs that support the glioblastoma (GBM) community during National Family Caregivers Month in November. Novocure will sponsor CURE magazine’s 2nd Annual GBM Heroes Recognition program, which honors those… Read More

METIS phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that the first patient has been enrolled in the METIS trial,… Read More

ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say “the three and nine months ended Sept. 30, 2016” rather than “the three and six months ended Sept. Read More

ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results… Read More

Guidelines provide a framework for using the NovoTAL System to optimize Tumor Treating Fields intensity in Optune patients Tumor Treating Fields extend overall survival when combined with maintenance temozolomide in newly diagnosed glioblastoma patients September 19, 2016 07:30 AM Eastern Daylight Time ST. HELIER,… Read More

The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms brings together thought leaders to advance this growing frontier of patient care September 15, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Executive Chairman William Doyle… Read More